Literature DB >> 1849034

Epstein-Barr virus in benign lymph node biopsies from individuals infected with the human immunodeficiency virus is associated with concurrent or subsequent development of non-Hodgkin's lymphoma.

D Shibata1, L M Weiss, B N Nathwani, R K Brynes, A M Levine.   

Abstract

Individuals infected with the human immunodeficiency virus (HIV) have an increased incidence of high-grade B-cell lymphoma. In many instances, these lymphomas contain Epstein-Barr viral (EBV) genomes. To investigate the role of EBV in development of HIV-related lymphoma, benign fixed lymph node biopsies from normal individuals and HIV-infected individuals with persistent generalized lymphadenopathy (PGL) were analyzed for EBV sequences by polymerase chain reaction and in situ DNA hybridization techniques. EBV DNA was not detected in any of 16 benign lymph node biopsies from normal individuals, but could be detected from 13 of 35 PGL biopsies. The EBV-infected cells were present in both follicular and interfollicular areas and in both small and large lymphoid cells. The presence of detectable amounts of EBV DNA in the 13 PGL biopsies was associated with an increased incidence of concurrent lymphoma at another site (n = 3) or development of lymphoma in time (n = 2). In contrast, only 1 of 22 individuals with EBV-negative PGL biopsies developed lymphoma in time (P less than .05). EBV was detected in all five lymphomas in which tissue was available for subsequent analysis, including the lymphoma that developed in the individual without EBV in his previous PGL biopsy. These findings support the hypothesis that EBV plays a role in development of some HIV-related lymphomas. Detectable EBV lymphoproliferations occur in a few PGL biopsies and are associated with a significant risk of EBV DNA-positive non-Hodgkin's lymphoma.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1849034

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  28 in total

Review 1.  Molecular diagnosis of Epstein-Barr virus-related diseases.

Authors:  M L Gulley
Journal:  J Mol Diagn       Date:  2001-02       Impact factor: 5.568

2.  Establishment of an HS23 stromal cell-dependent myeloma cell line: fibronectin and IL-6 are critical.

Authors:  Akira Sakai; Miyo Oda; Mitsuhiro Itagaki; Noriaki Yoshida; Koji Arihiro; Akiro Kimura
Journal:  Int J Hematol       Date:  2010-10-06       Impact factor: 2.490

3.  Epstein-Barr and human immunodeficiency viruses in acquired immunodeficiency syndrome-related primary central nervous system lymphoma.

Authors:  S Morgello
Journal:  Am J Pathol       Date:  1992-08       Impact factor: 4.307

4.  Detection of Epstein-Barr virus genome in Ki-1 (CD30)-positive, large-cell anaplastic lymphomas using the polymerase chain reaction.

Authors:  C W Ross; J A Schlegelmilch; T M Grogan; L M Weiss; B Schnitzer; C A Hanson
Journal:  Am J Pathol       Date:  1992-08       Impact factor: 4.307

5.  Epstein-Barr virus and Hodgkin's disease. A correlative in situ hybridization and polymerase chain reaction study.

Authors:  L M Weiss; Y Y Chen; X F Liu; D Shibata
Journal:  Am J Pathol       Date:  1991-12       Impact factor: 4.307

Review 6.  Lymphoproliferative disease in organ transplant recipients.

Authors:  M A Nalesnik
Journal:  Springer Semin Immunopathol       Date:  1991

Review 7.  Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts.

Authors:  R J O'Reilly; T N Small; E Papadopoulos; K Lucas; J Lacerda; L Koulova
Journal:  Springer Semin Immunopathol       Date:  1998

Review 8.  Pathogenesis of AIDS-related lymphomas: molecular and histogenetic heterogeneity.

Authors:  G Gaidano; A Carbone; R Dalla-Favera
Journal:  Am J Pathol       Date:  1998-03       Impact factor: 4.307

Review 9.  Malignant tumours in patients with HIV infection.

Authors:  U Tirelli; S Franceschi; A Carbone
Journal:  BMJ       Date:  1994-04-30

Review 10.  HIV-mediated B-lymphocyte activation and lymphomagenesis.

Authors:  J G Monroe; L E Silberstein
Journal:  J Clin Immunol       Date:  1995-03       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.